Christopher L Bowlus
Overview
Explore the profile of Christopher L Bowlus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
4288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levy C, Bowlus C
Hepatology
. 2024 Dec;
PMID: 39707635
Primary biliary cholangitis (PBC) is an enigmatic, autoimmune disease targeting the small intralobular bile ducts resulting in cholestasis and potentially progression to biliary cirrhosis. Primarily affecting middle-aged women, the diagnosis...
2.
Chan C, Lemos M, Finnegan P, Gagnon W, Dean R, Yazdanafar M, et al.
JHEP Rep
. 2024 Dec;
6(12):101188.
PMID: 39624235
Background & Aims: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with a strong association with inflammatory bowel disease and variable disease progression. We aimed to gain insights...
3.
Kowdley K, Hirschfield G, Coombs C, Malecha E, Bessonova L, Li J, et al.
Am J Gastroenterol
. 2024 Dec;
120(1):263.
PMID: 39621001
No abstract available.
4.
Bloemen H, Livanos A, Martins A, Dean R, Bravo A, Bourgonje A, et al.
Clin Gastroenterol Hepatol
. 2024 Nov;
PMID: 39490950
Background & Aims: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with...
5.
Kowdley K, Hirschfield G, Coombs C, Malecha E, Bessonova L, Li J, et al.
Am J Gastroenterol
. 2024 Aug;
120(2):390-400.
PMID: 39140490
Introduction: Obeticholic acid (OCA) treatment for primary biliary cholangitis (PBC) was conditionally approved in the phase 3 POISE trial. The COBALT confirmatory trial assessed whether clinical outcomes in patients with...
6.
Thorburn D, Leeming D, Barchuk W, Wang Y, Lu X, Malkov V, et al.
Hepatol Commun
. 2024 Jul;
8(7).
PMID: 38967589
Background: Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage...
7.
Li M, Pai R, Gomel R, Vyas M, Callif S, Hatchett J, et al.
Hepatol Commun
. 2024 May;
8(6).
PMID: 38727680
Background: According to the new AASLD Practice Guidance, all patients with primary sclerosing cholangitis (PSC) should be considered for participation in clinical trials. However, PSC's rarity has posed challenges to...
8.
Hirschfield G, Bowlus C, Mayo M, Kremer A, Vierling J, Kowdley K, et al.
N Engl J Med
. 2024 Feb;
390(9):783-794.
PMID: 38381664
Background: Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator-activated receptor delta agonist, has potential benefits. Methods: In this phase 3, 12-month, double-blind, placebo-controlled trial,...
9.
Mohamed R, Tejaswi S, Aabakken L, Ponsioen C, Bowlus C, Adler D, et al.
Endosc Int Open
. 2024 Feb;
12(2):E237-E244.
PMID: 38362361
Patients with primary sclerosing cholangitis (PSC) have a 9% to 20% lifetime incidence of cholangiocarcinoma (CCA). Per-oral cholangioscopy (POCS) added to endoscopic retrograde cholangiography (ERC) could potentially improve detection of...
10.
Zheng L, Tian S, Yang C, Li B, Jia G, Liu Y, et al.
Clin Gastroenterol Hepatol
. 2024 Feb;
22(6):1265-1274.e19.
PMID: 38354969
Background & Aims: Hypercholesterolemia is frequently diagnosed in patients with primary biliary cholangitis (PBC). However, its association with the prognosis and lipid metabolism is unknown. In this study, we aimed...